{"id":"W2296026603","doi":"10.1200/jco.2009.27.15_suppl.8597","title":"A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Refractory (planetary science); Internal medicine; Proteasome inhibitor; Lenalidomide; Oncology; Gastroenterology; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002307364,0.001809068,0.002336555,0.0006544939,0.0005081512,0.0008572331,0.001334108,0.001331404,0.003975748],"category_scores_gemma":[0.0008689645,0.0006823286,0.001125199,0.0006066522,0.0007667369,0.0007014912,0.0004768112,0.003416324,0.001201197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001117627,"about_ca_system_score_gemma":0.001592988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001235508,"about_ca_topic_score_gemma":0.002326579,"domain_scores_codex":[0.999314,0.0003318777,0.00003864252,0.0001021183,0.00007100673,0.0001424612],"domain_scores_gemma":[0.9992961,0.00009157819,0.0001260197,0.00007171786,0.00003816251,0.0003765201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7082565,0.09416255,0.01044117,0.0008335807,0.001509623,0.0007190919,0.0003570716,0.003441048,0.06471179,0.0004259418,0.007124043,0.1080176],"study_design_scores_gemma":[0.6437985,0.3388759,0.009748509,0.00003268631,0.0003430513,0.000433772,0.000026893,0.001169102,0.003343301,0.00009731128,0.002109885,0.00002106633],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898441,0.001868938,0.0005628636,0.0006059217,0.0001246919,0.003186892,0.0009582324,0.0001679145,0.002680302],"genre_scores_gemma":[0.9845234,0.001317333,0.003198546,0.001073574,0.0002763097,0.003685974,0.003297205,0.00003637407,0.002591341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003975748,"threshold_uncertainty_score":0.01330018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2983262679220963,"score_gpt":0.5394487551109878,"score_spread":0.2411224871888915,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}